Now that new mRNA manufacturing technologies have come seemingly out of nowhere to quickly produce billions of COVID-19 vaccine doses, companies are working to optimize them into robust platform technologies that could produce a whirlwind of innovative drug products now under development.
In a recent discussion on easing bottlenecks to meet the potential of mRNA, an expert panel explored a range of key manufacturing challenges and opportunities likely to influence the...